+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinases and angiogenesis



Matrix metalloproteinases and angiogenesis



Journal of Cellular and Molecular Medicine 9(2): 267-285



Matrix metalloproteinases (MMPs) are a family of enzymes that proteolytically degrade various components of the extracellular matrix (ECM). Angiogenesis is the process of forming new blood vessels from existing ones and requires degradation of the vascular basement membrane and remodeling of the ECM in order to allow endothelial cells to migrate and invade into the surrounding tissue. MMPs participate in this remodeling of basement membranes and ECM. However, it has become clear that MMPs contribute more to angiogenesis than just degrading ECM components. Specific MMPs have been shown to enhance angiogenesis by helping to detach pericytes from vessels undergoing angiogenesis, by releasing ECM-bound angiogenic growth factors, by exposing cryptic proangiogenic integrin binding sites in the ECM, by generating promigratory ECM component fragments, and by cleaving endothelial cell-cell adhesions. MMPs can also contribute negatively to angiogenesis through the generation of endogenous angiogenesis inhibitors by proteolytic cleavage of certain collagen chains and plasminogen and by modulating cell receptor signaling by cleaving off their ligand-binding domains. A number of inhibitors of MMPs that show antiangiogenic activity are already in early stages of clinical trials, primarily to treat cancer and cancer-associated angiogenesis. However, because of the multiple effects of MMPs on angiogenesis, careful testing of these MMP inhibitors is necessary to show that these compounds do not actually enhance angiogenesis.

(PDF emailed within 0-6 h: $19.90)

Accession: 066414701

Download citation: RISBibTeXText

PMID: 15963249

DOI: 10.1111/j.1582-4934.2005.tb00355.x


Related references

The expression of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and angiogenesis in relation to the depth of tumor invasion and lymph node metastasis in submucosally invasive colorectal carcinoma. Korean Journal of Gastroenterology 45(6): 401-408, 2005

Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations. Journal of Clinical Neuroscience 17(2): 232-236, 2010

Tissue inhibitor of metalloproteinases-1-mediated inhibition of in vitro angiogenesis is unrelated to its function as an inhibitor of matrix metalloproteinases. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 93, 1996

Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Research 65(8): 3193-3199, 2005

Matrix metalloproteinases and angiogenesis. Current Opinion in Nephrology and Hypertension 11(3): 295-299, 2002

Matrix metalloproteinases and matrikines in angiogenesis. Critical Reviews in Oncology/Hematology 49(3): 203-220, 2004

Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme and Protein 49(1-3): 117-137, 1996

The role of matrix metalloproteinases and their tissue inhibitors in angiogenesis. Polski Merkuriusz Lekarski 21(121): 80-85, 2006

Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. Journal of Biochemistry and Molecular Biology 36(1): 128-137, 2003

Matrix metalloproteinases -2 and -9 in pig luteal tissue angiogenesis and angioregression. Veterinary Research Communications 31(Suppl.1): 193-196, 2007

Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovascular Research 78(2): 203-212, 2007

Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discovery Today 6(9): 478-482, 2001

Effect of simvastatin on serum matrix metalloproteinases-1, matrix metalloproteinases-9, tissue inhibitor of metalloproteinases-1, high sensitive C-reactive protein levels in patients of acute coronary syndrome in serum normocholesterolemia and hypercholesterolemia level. Zhonghua Xinxueguanbing Zazhi 32(2): 109-113, February 19, 2004

Matrix metalloproteinases -2 and -9 in swine luteal tissue angiogenesis and angioregression. Veterinary Research Communications 31 Suppl 1: 193-196, 2007

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. Journal of Clinical Investigation 103(9): 1237-1241, 1999